ASTERDM Aster DM Healthcare Q2 FY26 results (Jul–Sep 2025) and concall
Aster DM Healthcare delivered a resilient Q2 FY26 performance characterized by a strong recovery in the Kerala cluster and significant progress toward its merger with Quality Care India Limited (QCIL). Despite softer seasonal volumes in North India/Bangalore, the company improved profitability through a richer specialty mix (Oncology) and cost-optimization initiatives like renewable energy. Management is pivoting toward a massive capacity expansion phase, targeting over 10,000 beds post-merger.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 10.2%, net profit up 14.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 1,086 | 1,050 | 1,000 | 1,078 | 1,197 +10% |
| EBITDA | 217 | 186 | 182 | 202 | 236 +9% |
| Net profit | 106 | 64 | 86 | 94 | 121 +14% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
